Data thru May 13, 2026
HomeTrendsArticlesDrug MarketsTherapeutic ClassesManufacturersPricingContact
Back to Market Feed

OLANZAPINE ODT 5 MG TABLET

olanzapine
$0.3120per EA

Strength

5 mg/1

Manufacturer

Strides Pharma Inc.

NDC

64380017202

Classification

Generic

Dosage Form

TABLET, ORALLY DISINTEGRATING

Route

ORAL

Last Updated

4/22/2026

Active Ingredients

OLANZAPINE

Approval Type

Generic (ANDA)

FDA Application

ANDA078109

On Market Since

4/11/2022

Pharmacological Classes

Atypical Antipsychotic

Price History

1W

0.0%

1M

+0.3%

3M

-1.9%

6M

-1.9%

1Y

+8.1%

3Y

-21.3%

5Y

N/A

All

-9.6%

Generic Alternatives

No alternatives available

No alternatives found with the same active ingredient, strength, and dosage form.

Related Drugs

Same classification

QUETIAPINE FUMARATE 25 MG TAB
Generic
00093206301•Teva Pharmaceuticals USA Inc.
$0.0289
per EA
QUETIAPINE FUMARATE 25 MG TAB
Generic
00904663861•Major Pharmaceuticals
$0.0289
per EA
QUETIAPINE FUMARATE 25 MG TAB
Generic
16571071701•Rising Pharma Holdings Inc.
$0.0289
per EA
QUETIAPINE FUMARATE 25 MG TAB
Generic
16571071710•Rising Pharma Holdings Inc.
$0.0289
per EA
QUETIAPINE FUMARATE 25 MG TAB
Generic
16714037501•NorthStar Rx LLC
$0.0289
per EA
QUETIAPINE FUMARATE 25 MG TAB
Generic
16714037502•NorthStar Rx LLC
$0.0289
per EA
QUETIAPINE FUMARATE 25 MG TAB
Generic
16729014501•Accord Healthcare Inc.
$0.0289
per EA
QUETIAPINE FUMARATE 25 MG TAB
Generic
16729014517•Accord Healthcare Inc.
$0.0289
per EA
QUETIAPINE FUMARATE 25 MG TAB
Generic
29300014701•Unichem Pharmaceuticals (USA) Inc.
$0.0289
per EA
QUETIAPINE FUMARATE 25 MG TAB
Generic
29300014710•Unichem Pharmaceuticals (USA) Inc.
$0.0289
per EA

Data Source

Pricing data sourced from the National Average Drug Acquisition Cost (NADAC) survey, published by the Centers for Medicare & Medicaid Services (CMS). Updated weekly.

Disclaimer

This site is for informational purposes only and does not constitute medical, pharmaceutical, or financial advice. NADAC prices are survey-based estimates and may not reflect actual acquisition costs at any specific pharmacy.

Navigate

HomeAboutManufacturersDrug MarketsTherapeutic ClassesTrendsArticlesPricingContact

© 2026 NADAC Intelligence. All rights reserved. Not affiliated with CMS or any government agency.

Terms of ServicePrivacy Policy